On a mission to
transform the future
of autoimmune care
Developing innovative therapies with the potential to redefine
the standard of care for autoimmune diseases.
Who We Are Jade
Jade
Biosciences
We are a clinical-stage company developing a pipeline of potentially best-in-class therapies aimed at transforming the standard of care for patients living with autoimmune diseases. Our programs build on discovery-stage assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
Jade’s lead candidate, JADE101, is designed to inhibit the cytokine APRIL (A PRoliferation-Inducing Ligand) and is being developed for the treatment of immunoglobulin A nephropathy (IgAN).